Pharmaceutical companies are increasingly seeking to enhance levels of brand differentiation within competitive therapeutic markets, improve the lifecycle management of their products and enhance levels of customer care. The introduction and enforcement of needlestick prevention laws within North America and Europe provide pharmaceutical companies with excellent opportunities to successfully market their drugs and vaccines for use within healthcare facilities or by patients that self-administer prescription medication at home.
The provision of prefilled syringes with an ancillary safety device, and the inclusion of a safety syringe within procedural kits are some examples of how needlestick prevention laws are being used by pharmaceutical companies to build the market value of their injectable drug products through helping to improve patient care, streamline healthcare procedures or protecting those at risk of harm or injury. Similar opportunities for brand differentiation can be secured through the packaging of drugs supplied in vial or ampoules with safety syringes in a convenient ‘ready-for-injection' kit.
Pharmaceutical opportunities for competitive brand differentiation can be further enhanced through the use of innovative drug delivery devices that uniquely address the safety and functionality requirements of customers, yet are only available with select drugs within a therapeutic market.